Review: An overview of the extra-lipid effects of rosuvastatin

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 13, Issue 3, 2008, Pages 157-174

  Kostapanos, Michael S ^a   Milionis, Haralampos J ^a   Elisaf, Moses S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Atherosclerosis; Extra lipid effects; Pleiotropic effects; Rosuvastatin; Safety

Indexed keywords

CANDESARTAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; N(G) NITROARGININE METHYL ESTER; ROSUVASTATIN; CARDIOTONIC AGENT; FIBRINOLYTIC AGENT; FLUOROBENZENE; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ATHEROSCLEROTIC PLAQUE; DRUG EFFECT; HEART MUSCLE; HEMOSTASIS; HUMAN; KIDNEY FUNCTION; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; REVIEW; ANIMAL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; KIDNEY; NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM; FIBRINOLYTIC AGENTS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; NERVOUS SYSTEM; PERIPHERAL NERVOUS SYSTEM; PYRIMIDINES; SULFONAMIDES;

EID: 49749115773     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/1074248408318628     Document Type: Review

References (130)

1. Ong HT The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM. 2005 ; 98: 599-614.
2. Sever PS DB, Poulter NR, Wedel H., et al, for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet. 2003 ; 361: 1149-1158.
3. LaRosa JC, Grundy SM, Waters DD, et al, for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 ; 352: 1-11.
4. Baigent C., Keech A., Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366: 1267-1278.
5. Costa J., Borges M., David C., Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and nondiabetic patients: meta-analysis of randomised controlled trials. BMJ. 2006 ; 332: 1115-1124.
6. WOSCOPS Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation. 1998 ; 97: 1440-1445.
7. Liao JK Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol. 2005 ; 96: 24F - 33F.
8. Kostapanos MS, Liberopoulos EN, Goudevenos JA, Mikhailidis DP, Elisaf MS Do statins have an antiarrhythmic activity ? Cardiovasc Res. 2007 ; 75: 10-20.
9. Liberopoulos EN, Daskalopoulou SS, Mikhailidis DP, Wierzbicki AS, Elisaf MS A review of the lipid-related effects of fluvastatin. Curr Med Res Opin. 2005 ; 21: 231-244.
10. Ray KK, Cannon CP, Ganz P. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials? Am J Cardiol. 2006 ; 98: 18P - 25P.
11. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 ; 92: 152-160.
12. Strandberg TE, Feely J., Sigurdsson EL Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin Ther. 2004 ; 26: 1821-1833.
13. Olsson A. Expanding options with a wider range of rosuvastatin doses. Clin Ther. 2006 ; 28: 1747-1763.
14. Schuster H. The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther. 2007 ; 5: 177-193.
15. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler Suppl. 2003 ; 4: 9-14.
16. Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007 ; 297: 1344-1353.
17. Nissen SE, Nicholls SJ, Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 ; 295: 1556-1565.
18. Schafer A., Fraccarollo D., Eigenthaler M., et al. Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability. Arterioscler Thromb Vasc Biol. 2005 ; 25: 1071-1077.
19. ter Avest E., Abbink EJ, Holewijn S., de Graaf J., Tack CJ, Stalenhoef AF Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH). Curr Med Res Opin. 2005 ; 21: 1469-1476.
20. Nangle MR, Cotter MA, Cameron NE Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice: relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. Diabetes. 2003 ; 52: 2396-2402.
21. Miller AW, Tulbert CD, Busija DW Rosuvastatin treatment reverses impaired coronary artery vasodilation in fructose-fed, insulin-resistant rats. Am J Physiol Regul Integr Comp Physiol. 2004 ; 287: R157 - R160.
22. Schafer A., Fraccarollo D., Vogt C., et al. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Biochem Pharmacol. 2007 ; 73: 1367-1375.
23. Sergienko IV, Samoilenko E., Masenko VP, et al. Effect of therapy with rosuvastatin on lipid spectrum, factors of inflammation and endothelial function in patients with ischemic heart disease. Kardiologiia. 2006 ; 46: 4-8.
24. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol. 2004 ; 94: 157-161.
25. van der Harst P., Groenwegen HC, Roks AJ, et al. Rosuvastatin attenuates angiotensin II-induced neointimal formation after stent implantation in the rat. Coron Artery Dis. 2008 ; 19: 47-53.
26. Landmesser U., Harrison DG Oxidant stress as a marker for cardiovascular events: Ox marks the spot. Circulation. 2001 ; 104: 2638-2640.
27. Jantzen F., Koneman S., Wolff B., et al. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells. J Physiol Pharmacol. 2007 ; 58: 503-514.
28. Haas MJ, Horani MH, Parseghian SA, Mooradian AD Statins prevent dextrose-induced endothelial barrier dysfunction, possibly through inhibition of superoxide formation. Diabetes. 2006 ; 55: 474-479.
29. Chen J., Li D., Schaefer R., Mehta JL Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis. 2006 ; 184: 295-301.
30. Enomoto S., Sata M., Fukuda D., Nakamura K., Nagai R. Rosuvastatin prevents endothelial cell death and reduces atherosclerotic lesion formation in ApoE-deficient mice [published online ahead of print December 10, 2007]. Biomed Pharmacother. doi:10.1016/j.biopha.2007.11.002.
31. Desjardins F., Sekkali B., Verreth W., et al. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice. Eur Heart J. 2008 ; 29: 128-137.
32. ter Avest E., Abbink EJ, de Graaf J., Tack CJ, Stalenhoef AF Effect of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidaemia. Eur J Clin Invest. 2005 ; 35: 558-564.
33. Resch U., Tatzber F., Budinsky A., Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol. 2006 ; 61: 262-274.
34. Otto A., Fontaine J., Tschirhart E., Fontaine D., Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress in eNOS knockout mice: implication of the NAD(P)H oxidase pathway. Br J Pharmacol. 2006 ; 148: 544-552.
35. Otto A., Fontaine D., Fontaine J., Berkenboom G. Rosuvastatin treatment protects against nitrate-induced oxidative stress. J Cardiovasc Pharmacol. 2005 ; 46: 177-184.
36. Li W., Asagami T., Matsushita H., Lee KH, Tsao PS Rosuvastatin attenuates monocyte-endothelial cell interactions and vascular free radical production in hypercholesterolemic mice. J Pharmacol Exp Ther. 2005 ; 313: 557-562.
37. Muchova L., Wong RJ, Hsu M., et al. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can J Physiol Pharmacol. 2007 ; 85: 800-810.
38. Bergheanu SC, van Tol A., Dallinga-Thie GM, et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin. 2007 ; 23: 2235-2240.
39. Miersch S., Sliskovic I., Raturi A., Mutus B. Antioxidant and antiplatelet effects of rosuvastatin in a hamster model of prediabetes. Free Radic Biol Med. 2007 ; 42: 270-279.
40. Schupp N., Schmid U., Heidland A., Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis [published online ahead of print December 21, 2007]. Atherosclerosis. doi:10.1016/j.atherosclerosis.2007.11.016.
41. Grosser N., Erdmann K., Hemmerle A., et al. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochem Biophys Res Commun. 2004 ; 325: 871-876.
42. Pirro M., Schillaci G., Mannarino MR, et al. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2007 ; 17: 436-441.
43. Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin. 2006 ; 22: 2041-2053.
44. Milionis HJ, Gazi IF, Filippatos TD, et al. Starting with rosuvastatin in primary hyperlipidemia-is there more than lipid lowering ? Angiology. 2005 ; 56: 585-592.
45. Milionis HJ, Rizos E., Kostapanos M., et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin. 2006 ; 22: 1123-1131.
46. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol. 2007 ; 49: 554-561.
47. Ridker PM Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003 ; 108: 2292-2297.
48. Kleemann R., Princen HM, Emeis JJ, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Circulation. 2003 ; 108: 1368-1374.
49. Saougos VG, Tambaki AP, Kalogirou M., et al. Differential effect of hypolipidaemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007 ; 27: 2236-2243.
50. Kostapanos MS, Derdemezis CS, Filippatos TD, et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol. 2007 ; 578: 249-252.
51. Link A., Ayadhi T., Bohm M., Nickenig G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J. 2006 ; 27: 2945-2955.
52. Kim YS, Ahn Y., Hong MH, et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and Nuclear Factor-kappaB in endothelial cells. J Cardiovasc Pharmacol. 2007 ; 49: 376-383.
53. van Oostrom AJ, Plokker HW, van Asbeck BS, et al. Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis. Atherosclerosis. 2006 ; 185: 331-339.
54. Chen J., Li D., Schaefer RF, Mehta JL Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis. J Cardiovasc Pharmacol. 2004 ; 44: 446-452.
55. Schmidt WM, Spiel AO, Jilma B., Wolzt M., Müller M. Invivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 ; 18: 109-120.
56. Monetti M., Canavesi M., Camera M., et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacol Res. 2007 ; 55: 441-449.
57. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol. 2001 ; 133: 406-412.
58. Furman C., Copin C., Kandoussi M., et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis. 2004 ; 174: 93-98.
59. Underhill HR, Yuan C., Zhao XQ, et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J. 2008 ; 155: 584.e1-e8.
60. Werner N PJ, Laufs U., Endres M., Böhm M., Dirnagl U., Nickenig G. Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol. 2002 ; 22: 1567-1572.
61. Kappert K., Leppanen O., Paulsson J., et al. Highly active antiretroviral therapy attenuates re-endothelialization and alters neointima formation in the rat carotid artery after balloon injury. J Acquir Immune Defic Syndr. 2006 ; 43: 383-392.
62. Thum T., Tsikas D., Stein S., et al. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol. 2005 ; 46: 1693-1701.
63. Kiyan J., Kusch A., Tkachuk S., et al. Rosuvastatin regulates vascular smooth muscle cell phenotypic modulation in vascular remodeling: role for the urokinase receptor. Atherosclerosis. 2007 ; 195: 254-261.
64. Weiss S., Frischknecht K., Greutert H., et al. Different migration of vascular smooth muscle cells from human coronary artery bypass vessels. Role of Rho/ROCK pathway. J Vasc Res. 2007 ; 44: 149-156.
65. Schafer K., Kaiser K., Konstantinides S. Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injury. Thromb Haemost. 2005 ; 93: 145-152.
66. Verreth W., De Keyzer D., Davey PC, et al. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. Br J Pharmacol. 2007 ; 151: 347-355.
67. Coban E Md, Afacan B. The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment. Platelets. 2007 ; 23: 1-4.
68. Serebruany VL, Miller M., Pokov AN, et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). Am J Cardiol. 2006 ; 97: 1332-1336.
69. Laumen H., Skurk T., Hauner H. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis. 2008 ; 196: 565-573.
70. Naples M., Federico LM, Xu E., Nelken J., Adeli K. Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization. Atherosclerosis. 2008 ; 198: 94-103.
71. Lamendola C., Abbasi F., Chu JW, et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol. 2005 ; 95: 189-193.
72. Bulhak AA, Gourine AV, Gonon AT, Sjoquist PO, Valen G., Pernow J. Oral pre-treatment with rosuvastatin protects porcine myocardium from ischaemia/reperfusion injury via a mechanism related to nitric oxide but not to serum cholesterol level. Acta Physiol Scand. 2005 ; 183: 151-159.
73. Di Napoli P., Taccardi AA, Grilli A., et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res. 2005 ; 66: 462-471.
74. Weinberg EO, Scherrer-Crosbie M., Picard MH, et al. Rosuvastatin reduces experimental left ventricular infarct size after ischemia-reperfusion injury but not total coronary occlusion. Am J Physiol Heart Circ Physiol. 2005 ; 288: H1802 - H1809.
75. Jones SP, Gibson MF, Rimmer DM 3rd, Gibson TM, Sharp BR, Lefer DJ Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-CoA reductase inhibitor. J Am Coll Cardiol. 2002 ; 40: 1172-1178.
76. Ikeda Y., Young LH, Lefer AM Rosuvastatin, a new HMG-CoA reductase inhibitor, protects ischemic reperfused myocardium in normocholesterolemic rats. J Cardiovasc Pharmacol. 2003 ; 41: 649-656.
77. Bulhak A., Roy J., Hedin U., Sjoquist PO, Pernow J. Cardioprotective effect of rosuvastatin in vivo is dependent on inhibition of geranylgeranyl pyrophosphate and altered RhoA membrane translocation. Am J Physiol Heart Circ Physiol. 2007 ; 292: H3158 - H3163.
78. Custodis F., Eberl M., Kilter H., Bohm M., Laufs U. Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy. Cardiovasc Res. 2006 ; 71: 342-351.
79. Takemoto M., Node K., Nakagami H., et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001 ; 108: 1429-1437.
80. Maack C., Kartes T., Kilter H., et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation. 2003 ; 108: 1567-1574.
81. Li JM, Gall NP, Grieve DJ, Chen M., Shah AM Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 2002 ; 40: 477-484.
82. Adra CN, Manor D., Ko JL, et al. RhoGDIgamma: a GDPdissociation inhibitor for Rho proteins with preferential expression in brain and pancreas. Proc Natl Acad Sci U S A. 1997 ; 94: 4279-4284.
83. Habibi J., Whaley-Connell A., Qazi MA, et al. Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology. 2007 ; 148: 2181-2188.
84. Sun X., Ku DD Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol. 2008 ; 294: H801 - H809.
85. Cirrincione GM, Boluyt MO, Hwang HS, Bleske BE 3-HMG-Coenzyme A reductase inhibition and extracellular matrix gene expression in the pressure-overloaded rat heart. J Cardiovasc Pharmacol. 2006 ; 47: 521-530.
86. Krum H., Ashton E., Reid C., et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail. 2007 ; 13: 1-7.
87. Pelat M., Dessy C., Massion P., Desager JP, Feron O., Balligand JL Rosuvastatin decreases caveolin-1 and improves nitric oxide-dependent heart rate and blood pressure variability in apolipoprotein E-/- mice in vivo. Circulation. 2003 ; 107: 2480-2486.
88. Sega R., Corrao G., Bombelli M., et al. Blood pressure variability and organ damage in a general population: results from the PAMELA study (Pressioni Arteriose Monitorate E Loro Associazioni). Hypertension. 2002 ; 39: 710-714.
89. Stauss HM, Persson PB Role of nitric oxide in buffering short-term blood pressure fluctuations. News Physiol Sci. 2000 ; 15: 229-233.
90. Talini E., DiBello V., Bianchi C., et al. Early impairment of left ventricular function in hypercholesterolemia and its reversibility after short term treatment with rosuvastatin. A preliminary echocardiographic study. Atherosclerosis. 2008 ; 197: 346-354.
91. Kjekshus J., Apetrei E., Barrios V.,, et al. CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007 ; 357: 2248-2261.
92. Laufs U., Gertz K., Dirnagl U., Bohm M., Nickenig G., Endres M. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res. 2002 ; 942: 23-30.
93. Xing H., Sun S., Mei Y., Herman D. The protective effect of rosuvastatin on ischemic brain injury and its mechanism. J Huazhong Univ Sci Technolog Med Sci. 2006 ; 26: 667-669.
94. Engelhorn T., Doerfler A., Heusch G., Schulz R. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats. Neurosci Lett. 2006 ; 406: 92-96.
95. Prinz V., Laufs U., Gertz K., et al. Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke. 2008 ; 39: 433-438.
96. Kilic U., Bassetti CL, Kilic E., Xing H., Wang Z., Hermann DM Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2. Neuroscience. 2005 ; 134: 901-906.
97. Kilic E., Kilic U., Matter CM, Luscher TF, Bassetti CL, Hermann DM Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase. Stroke. 2005 ; 36: 332-336.
98. Zacco A., Togo J., Spence K., et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci. 2003 ; 23: 11104-11111.
99. Erdos B., Snipes JA, Tulbert CD, Katakam P., Miller AW, Busija DW Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD(P)H oxidase-dependent superoxide production. Am J Physiol Heart Circ Physiol. 2006 ; 290: H1264 - H1270.
100. Hsu M., Muchova L., Morioka I., Wong RJ, Schroder H., Stevenson DK Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo. Biochem Biophys Res Commun. 2006 ; 343: 738-744.
101. Sironi L., Gianazza E., Gelosa P., et al. Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects. Arterioscler Thromb Vasc Biol. 2005 ; 25: 598-603.
102. Famer D., Crisby M. Rosuvastatin reduces caspase-3 activity and up-regulates alpha-secretase in human neuroblastoma SH-SY5Y cells exposed to A beta. Neurosci Lett. 2004 ; 371: 209-214.
103. Gastard MC, Troncoso JC, Koliatsos VE Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol. 2003 ; 54: 393-398.
104. Selkoe DJ Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001 ; 81: 741-766.
105. Minagar A., Shapshak P., Fujimura R., Ownby R., Heyes M., Eisdorfer C. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci. 2002 ; 202: 13-23.
106. Famer D., Crisby M. Rosuvastatin reduces gliosis and the accelerated weight gain observed in WT and ApoE-/mice exposed to a high cholesterol diet. Neurosci Lett. 2007 ; 419: 68-73.
107. Roensch J., Crisby M., Nordberg A., Xiao Y., Zhang LJ, Guan ZZ Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochem Int. 2007 ; 50: 800-806.
108. Ii M., Nishimura H., Kusano KF, et al. Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy. Circulation. 2005 ; 112: 93-102.
109. Oltman CL, Davidson EP, Coppey LJ, Kleinschmidt TL, Lund DD, Yorek MA Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Obesity (Silver Spring). 2008 ; 16: 82-89.
110. Oltman CL, Davidson EP, Coppey LJ, et al. Vascular and neural dysfunction in Zucker diabetic fatty rats: a difficult condition to reverse. Diabetes Obes Metab. 2008 ; 10: 64-74.
111. Vidt DG, Harris S., McTaggart F., Ditmarsch M., Sager PT, Sorof JM Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol. 2006 ; 97: 1602-1606.
112. Vidt DG, Cressman MD, Harris S., Pears JS, Hutchinson HG Rosuvastatin-induced arrest in progression of renal disease. Cardiology. 2004 ; 102: 52-60.
113. Verma A., Ranganna KM, Reddy RS, Verma M., Gordon NF Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol. 2005 ; 96: 1290-1292.
114. Sorof J., Berne C., Siewert-Delle A., Jorgensen L., Sager P. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Res Clin Pract. 2006 ; 72: 81-87.
115. Kostapanos MS, Milionis HJ, Gazi I., Kostara C., Bairaktari ET, Elisaf M. Rosuvastatin increases alpha-1 microglobulin urinary excretion in patients with primary dyslipidemia. J Clin Pharmacol. 2006 ; 46: 1337-1343.
116. Kostapanos MS, Milionis HJ, Saougos VG, et al. Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. J Cardiovasc Pharmacol Ther. 2007 ; 12: 292-297.
117. Gianella A., Nobili E., Abbate M., et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol. 2007 ; 170: 1165-1177.
118. Whaley-Connell A., DeMarco VG, Lastra G., et al. Insulin resistance, oxidative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. Am J Nephrol. 2008 ; 28: 67-75.
119. Whaley-Connell A., Habibi J., Nistala R., et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension. 2008 ; 51: 474-480.
120. Krämer S., Kron S., Wang-Rosenke Y., et al. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangioproliferative glomerulosclerosis. Am J Physiol Renal Physiol. 2008 ; 294: F801 - F811.
121. Whaley-Connell AT, Morris EM, Rehmer N., et al. Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells. Am J Nephrol. 2007 ; 27: 15-23.
122. Ott C., Schlaich MP, Schmidt BM, Titze SI, Schaufele T., Schmieder RE Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis. 2007 ; 196: 704-711.
123. Tiwari A. An overview of statin-associated proteinuria. Drug Discov Today. 2006 ; 11: 458-464.
124. Corna D SF, Cattaneo D., Carrara F., et al. Effects of rosuvastatin on glomerular capillary size-selectivity function in rats with renal mass ablation. Am J Nephrol. 2007 ; 27: 630-638.
125. Sidaway JE, Davidson RG, McTaggart F., et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol. 2004 ; 15: 2258-2265.
126. Verhulst A., D'Haese PC, De Broe ME Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol. 2004 ; 15: 2249-2257.
127. Naito Y., Katada K., Takagi T., et al. Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice. Int J Mol Med. 2006 ; 17: 997-1004.
128. Naito Y., Katada K., Takagi T., et al. Rosuvastatin reduces rat intestinal ischemia-reperfusion injury associated with the preservation of endothelial nitric oxide synthase protein. World J Gastroenterol. 2006 ; 12: 2024-2030.
129. Antonopoulos S., Mikros S., Mylonopoulou M., Kokkoris S., Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis. 2006 ; 184: 233-234.
130. Ferdinand KC Rosuvastatin: a risk-benefit assessment for intensive lipid lowering. Expert Opin Pharmacother. 2005 ; 6: 1897-1910.